Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​

Abstract Olverembatinib is a novel third-generation TKI available in mainland China. However, there are only a few published clinical reports. In this study, we aimed to investigate the efficacy and safety of an olverembatinib-venetoclax regimen before bridging to HSCT in adult Ph/BCR-ABL1 + ALL pat...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Xiaoyu Zhang, Yanhong Zhao, Weihua Zhai, Qiaoling Ma, Yigeng Cao, Jialin Wei, Chen Liang, Xin Chen, Wenbin Cao, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Springer 2025-12-01
श्रृंखला:	Annals of Hematology
विषय:	Ph + ALL Olverembatinib Allo-HSCT Venetoclax Complete molecular remission
ऑनलाइन पहुंच:	https://doi.org/10.1007/s00277-025-06708-0
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!